Literature DB >> 35902440

Structural and functional changes among diabetics with no diabetic retinopathy and mild non-proliferative diabetic retinopathy using swept-source optical coherence tomography angiography and photopic negative response.

Karthika Pandurangan1, Ramya Sachidanandam1, Parveen Sen2.   

Abstract

PURPOSE: To assess the structural and functional changes among diabetics with no diabetic retinopathy (NDR) and mild non-proliferative diabetic retinopathy (NPDR) using swept-source optical coherence tomography angiography (SSOCTA) and photopic negative response (PhNR) and to find the earliest changes.
METHODS: This was a prospective, cross-sectional, case-control study. Participants with minimum 5 years of diabetes mellitus (DM) were recruited and classified as NDR and mild NPDR based on fundus findings. Age-matched normals with nil ocular pathology were considered as controls. SSOCTA scan acquisition (6*6 mm angiography), followed by full field photopic electroretinography (FFERG) and red on blue PhNR (R/B PhNR) were done with complete pupillary dilatation.
RESULTS: A total of 88 participants were included with 35 controls, 39 NDR and 14 mild NPDR subjects. Vessel density of the superficial capillary plexus (SCP) and deep capillary plexus (DCP) of mild NPDR were significantly reduced compared to the controls (17.12 ± 2.65 mm-1 vs. 18.75 ± 0.90 mm-1, p = 0.025 and 7.96 ± 3.92 mm-1 vs. 11.83 ± 3.05 mm-1, p = 0.001 respectively). None of the parameters of controls had significant difference compared to NDR group (p > 0.05). The amplitudes of white on white (W/W) a-wave, W/W b-wave, red on blue (R/B) PhNR baseline to trough (BT) and R/B PhNR peak to trough in controls were significantly high compared to NDR and mild NPDR. Amplitude of R/B PhNR BT had the maximum area under the curve of 75.9% with a sensitivity and specificity of 94.3and 77.4%, respectively.
CONCLUSION: A significant decrease in functional changes as measured by ERG especially PhNR, is seen even among the NDR group compared to controls unlike SSOCTA parameters that measures very early vascular structural changes. PhNR is a sensitive test to identify early preclinical changes in DR when microvascular structural changes as determined by SSOCTA are normal.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Electrophysiology; Microvascular complication; Neuronal; Retinal ganglion cell

Mesh:

Year:  2022        PMID: 35902440     DOI: 10.1007/s10633-022-09891-x

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   1.854


  35 in total

1.  Changes of oscillatory potentials and photopic negative response in patients with early diabetic retinopathy.

Authors:  Junya Kizawa; Shigeki Machida; Takaki Kobayashi; Yasutaka Gotoh; Daijiro Kurosaka
Journal:  Jpn J Ophthalmol       Date:  2006 Jul-Aug       Impact factor: 2.447

2.  Retinal neurovascular changes appear earlier in type 2 diabetic patients.

Authors:  Luisa Pierro; Lorenzo Iuliano; Maria Vittoria Cicinelli; Giuseppe Casalino; Francesco Bandello
Journal:  Eur J Ophthalmol       Date:  2016-10-22       Impact factor: 2.597

3.  Morphological and functional analyses of diabetic macular edema by optical coherence tomography and multifocal electroretinograms.

Authors:  S Yamamoto; T Yamamoto; M Hayashi; S Takeuchi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2001-02       Impact factor: 3.117

4.  Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition.

Authors:  Pouya Saeedi; Inga Petersohn; Paraskevi Salpea; Belma Malanda; Suvi Karuranga; Nigel Unwin; Stephen Colagiuri; Leonor Guariguata; Ayesha A Motala; Katherine Ogurtsova; Jonathan E Shaw; Dominic Bright; Rhys Williams
Journal:  Diabetes Res Clin Pract       Date:  2019-09-10       Impact factor: 5.602

5.  Does neuronal damage precede vascular damage in subjects with type 2 diabetes mellitus and having no clinical diabetic retinopathy?

Authors:  Aditya Verma; Rajiv Raman; K Vaitheeswaran; Swakshyar Saumya Pal; Gella Laxmi; Muneeswar Gupta; S Chandra Shekar; Tarun Sharma
Journal:  Ophthalmic Res       Date:  2011-12-16       Impact factor: 2.892

6.  Decreased retinal ganglion cell layer thickness in patients with type 1 diabetes.

Authors:  Hille W van Dijk; Frank D Verbraak; Pauline H B Kok; Mona K Garvin; Milan Sonka; Kyungmoo Lee; J Hans Devries; Robert P J Michels; Mirjam E J van Velthoven; Reinier O Schlingemann; Michael D Abràmoff
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-02-03       Impact factor: 4.799

7.  Clinical applications of photopic negative response (PhNR) for the treatment of glaucoma and diabetic retinopathy.

Authors:  Hoon Dong Kim; Joo Youn Park; Young-Hoon Ohn
Journal:  Korean J Ophthalmol       Date:  2010-04-06

Review 8.  Vascular Changes and Neurodegeneration in the Early Stages of Diabetic Retinopathy: Which Comes First?

Authors:  Karoline Boegeberg Jonsson; Ulrik Frydkjaer-Olsen; Jakob Grauslund
Journal:  Ophthalmic Res       Date:  2016-04-02       Impact factor: 2.892

Review 9.  Global prevalence and major risk factors of diabetic retinopathy.

Authors:  Joanne W Y Yau; Sophie L Rogers; Ryo Kawasaki; Ecosse L Lamoureux; Jonathan W Kowalski; Toke Bek; Shih-Jen Chen; Jacqueline M Dekker; Astrid Fletcher; Jakob Grauslund; Steven Haffner; Richard F Hamman; M Kamran Ikram; Takamasa Kayama; Barbara E K Klein; Ronald Klein; Sannapaneni Krishnaiah; Korapat Mayurasakorn; Joseph P O'Hare; Trevor J Orchard; Massimo Porta; Mohan Rema; Monique S Roy; Tarun Sharma; Jonathan Shaw; Hugh Taylor; James M Tielsch; Rohit Varma; Jie Jin Wang; Ningli Wang; Sheila West; Liang Xu; Miho Yasuda; Xinzhi Zhang; Paul Mitchell; Tien Y Wong
Journal:  Diabetes Care       Date:  2012-02-01       Impact factor: 19.112

10.  ISCEV extended protocol for the photopic negative response (PhNR) of the full-field electroretinogram.

Authors:  Laura Frishman; Maja Sustar; Jan Kremers; J Jason McAnany; Marc Sarossy; Radouil Tzekov; Suresh Viswanathan
Journal:  Doc Ophthalmol       Date:  2018-05-31       Impact factor: 2.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.